HMG-CoA Reductase Inhibitor (Statin) Therapy and Coronary Atherosclerosis in Japanese Subjects: Role of High-Density Lipoprotein Cholesterol

Author： Tani Shigemasa   Nagao Ken   Hirayama Atsushi  

Publisher： Adis International

ISSN： 1175-3277

Source： American Journal of Cardiovascular Drugs, Vol.11, Iss.6, 2011-12, pp. : 411-417

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

HMG CoA reductase inhibitor [statin] therapy should be considered for older patients

By  

Inpharma, Vol. 1, Iss. 1237, 2000-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

HMG-CoA reductase inhibitor, fluvastatin, has cholesterol-lowering independent ''direct'' effects on atherosclerotic vessels in high cholesterol diet-fed rabbits

By Mitani H.   Egashira K.   Kimura M.  

Pharmacological Research, Vol. 48, Iss. 5, 2003-11 ,pp. : 417-427

Elsevier

Access to resources Recommend Favorite

Pluripotential Mechanisms of Cardioprotection with HMG-CoA Reductase Inhibitor Therapy

By Rosenson R.S.  

American Journal of Cardiovascular Drugs, Vol. 1, Iss. 6, 2001-06 ,pp. : 411-420

Adis International

Access to resources Recommend Favorite

High-Density Lipoprotein: Key Molecule in Cholesterol Efflux and the Prevention of Atherosclerosis

By  

Current Pharmaceutical Design, Vol. 16, Iss. 13, 2010-05 ,pp. : 1445-1467

Bentham Science Publishers

Access to resources Recommend Favorite

High Density Lipoprotein Cholesterol and Statin Trials

By  

Current Medicinal Chemistry, Vol. 15, Iss. 22, 2008-09 ,pp. : 2265-2270

Bentham Science Publishers

Access to resources Recommend Favorite